Related Experiment Video
Updated: Aug 14, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Attenuation of immune complex nephritis in NZB/WF1 mice by a prostacyclin analogue
Y Utsunomiya1, M Ogura, T Kawamura
1Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
Abstract:
Although prostaglandins have been shown to inhibit the evolution of the nephritis in NZB/W mice, the mechanisms of this effect are unknown. To characterize such inhibition, we injected the prostacyclin (PGI2) analogue, beraprost, into NZB/W mice, using 0.5 mg, 1.0 mg or 5.0 mg beraprost/kg body weight of test animals three times in 1 week when the mice were 2 months old. Evaluation included measurement of urine albumin excretion, serological parameters and splenic T cell subset, as well as examination of renal histology by light and fluorescence microscopy. Mice given beraprost showed a marked decrease in urine albumin excretion and in glomerular hypercellularity compared with untreated controls. Maximal beneficial effects occurred when the dose was 5.0 mg/kg of beraprost. These effects correlated with a reduction of immune complex deposition in glomeruli. In addition, beraprost reduced serum levels of immunoglobulins and anti-double-stranded DNA antibodies, and decreased the number of helper (L3T4+) T cells in splenocytes. These results indicate that beraprost attenuates the nephritis of NZB/W mice, and that the source of this effect is the reduced production of autoantibodies and deposition of immune complexes in glomeruli.
Insights
Beraprost, a prostacyclin analogue, significantly reduced nephritis in NZB/W mice by decreasing autoantibodies and immune complex deposition. This study clarifies the mechanisms behind prostaglandin inhibition of autoimmune kidney disease.
Area of Science:
- Immunology
- Nephrology
- Pharmacology
Background:
- Prostaglandins are known to inhibit nephritis progression in NZB/W mice.
- The precise mechanisms underlying this inhibitory effect remain largely unknown.
Purpose of the Study:
- To investigate the inhibitory effects of a prostacyclin (PGI2) analogue, beraprost, on nephritis in NZB/W mice.
- To elucidate the mechanisms by which beraprost attenuates autoimmune kidney disease.
Main Methods:
- NZB/W mice were administered varying doses of beraprost (0.5, 1.0, or 5.0 mg/kg) over one week.
- Evaluations included urine albumin excretion, serological markers, splenic T cell subsets, and renal histology.
- Light and fluorescence microscopy were used for histological examination.
Main Results:
- Beraprost treatment led to a significant reduction in urine albumin excretion and glomerular hypercellularity.
- Maximal therapeutic effects were observed at a beraprost dose of 5.0 mg/kg.
- Reduced immune complex deposition, lower immunoglobulin and anti-dsDNA antibody levels, and decreased helper T cells were noted.
Conclusions:
- Beraprost effectively attenuates nephritis in NZB/W mice.
- The therapeutic benefits are attributed to reduced autoantibody production and immune complex deposition in the glomeruli.
More Related Videos
11:47Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes
Published on: March 4, 2022
14:18Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
Published on: October 13, 2023